Medically reviewed by Susan Russell, MD Key Takeaways Squamous cell carcinoma begins in the tissues lining the air passages ...

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...

Although exposure to ultraviolet rays is a primary cause of skin cancer, factors such as your age, sex, and smoking habits also may contribute to developing this health issue.

The three types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and melanoma. Here's how to identify their ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic ...

A new large-scale study has found that nicotinamide, a common vitamin B3 supplement, may significantly reduce the risk of ...

Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing ...

Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence ...

The US FDA has granted breakthrough therapy designation (BTD) to the bifunctional antibody ficerafusp alfa (BCA101) in ...